As the global competition between new treatments for hemophilia is set to become ever more crowded, worldwide blockbuster Hemlibra (emicizumab) has expanded its indications in Japan, while positive new Phase III results presented for mild/moderate hemophilia A are set to support an approval filing in this setting in Europe.
The Factor IXa- and X-directed bispecific antibody, created by Chugai Pharmaceutical Co., Ltd. and developed/commercialized together with parent Roche Holding AG and Genentech, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?